A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

• Status: Recruiting
• Trial end date: 2022-01-30
• Target enrollment: 0
• Participant gender: All

Summary

This is an open, multicenter phase II clinical study for PLM60. The primary aim of the study is to observe the initial efficacy of PLM60 in treatment of small cell lung cancer. The secondary aim is to explore the safety and PK characteristics of PLM60

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Criteria

Inclusion Criteria:

1. Histologically confirmed diagnosis of SCLC;

2. Must have recurrence or progression after platinum-based first-line chemotherapy or chemoradiation therapy for the treatment of SCLC;

3. ECOG performance status 0~2;

4. Measurable lesion according to RECIST v1.1;

5. Life expectancy ≥ 12 weeks;

6. Adequate organ function;

7. Signed informed consent from the patient.

Exclusion Criteria:

1. Radical surgical treatment for primary small cell lung cancer;

2. Any anti-tumor treatment received within 4 weeks before the first use of the study drug;

3. Untreated or symptomatic central nervous system (CNS) metastases;

4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;

5. History of serious systemic diseases;

6. History of serious autoimmune diseases;

7. Those receiving treatment of adriamycin or other anthracyclines previously, with the total cumulative adriamycin (or adriamycin-equivalent) dose of >360 mg/m2.